A hypoxia-activated NO donor for the treatment of myocardial hypoxia injury.
Journal
Chemical science
ISSN: 2041-6520
Titre abrégé: Chem Sci
Pays: England
ID NLM: 101545951
Informations de publication
Date de publication:
24 Mar 2022
24 Mar 2022
Historique:
received:
05
01
2022
accepted:
28
02
2022
entrez:
18
4
2022
pubmed:
19
4
2022
medline:
19
4
2022
Statut:
epublish
Résumé
As present NO donor drugs cannot localize to release NO at the hypoxic site, along with the short half-life and bidirectional regulation of NO, they are unable to overcome low bioavailability and side effects in the treatment of myocardial hypoxia injury. In this study, we designed and prepared a novel hypoxia-activated NO donor (Hano) by hybridization of a known NO donor compound (Nno) with a hypoxia-activated group. Hano and isosorbide dinitrate were compared in terms of NO release and anti-myocardial hypoxia injury. Furthermore, the effects of Hano and Nno on releasing NO, dilating blood vessels, and preventing myocardial hypoxia injury were studied and compared in smooth muscle cells, cardiomyocytes and mice. The results showed that the NO release by Hano increased either in smooth muscle cells or in myocardial cells under hypoxia conditions. Significantly, Hano was found capable of dilating blood vessels and attenuating hypoxia injury both
Identifiants
pubmed: 35432877
doi: 10.1039/d2sc00048b
pii: d2sc00048b
pmc: PMC8943891
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3549-3555Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
Free Radic Biol Med. 2018 Mar;117:76-89
pubmed: 29373843
Nature. 2019 Feb;566(7743):264-269
pubmed: 30700906
Nat Med. 2011 Nov 07;17(11):1391-401
pubmed: 22064429
Cardiovasc Res. 2017 Jan;113(1):15-29
pubmed: 27742621
Angew Chem Int Ed Engl. 2020 May 25;59(22):8512-8516
pubmed: 32212410
Cardiovasc Res. 2019 Mar 1;115(3):625-636
pubmed: 30165375
Cardiovasc Res. 2021 Jan 1;117(1):162-177
pubmed: 32077922
Small. 2020 Jul;16(27):e1907635
pubmed: 32372556
Antioxid Redox Signal. 2015 Oct 10;23(11):899-942
pubmed: 26261901
Clin Cancer Res. 2017 May 15;23(10):2382-2390
pubmed: 28137923
Eur Heart J. 2012 Apr;33(7):829-37, 837a-837d
pubmed: 21890489
Eur J Med Chem. 2017 May 26;132:135-141
pubmed: 28350997
JAMA. 2019 Mar 26;321(12):1200-1210
pubmed: 30912843
Nanoscale. 2021 Jan 21;13(2):444-459
pubmed: 33403376
Adv Sci (Weinh). 2018 Apr 23;5(6):1701043
pubmed: 29938181
Nat Protoc. 2016 Apr;11(4):781-94
pubmed: 27010756
Theranostics. 2018 Nov 15;8(21):6025-6034
pubmed: 30613279
Circ Res. 2017 Feb 17;120(4):713-735
pubmed: 28209797
J Med Chem. 2020 Jan 9;63(1):186-204
pubmed: 31820986
Physiol Rev. 2019 Jan 1;99(1):311-379
pubmed: 30379623
Nat Commun. 2019 Jun 27;10(1):2824
pubmed: 31249305
Nat Commun. 2016 Oct 26;7:13187
pubmed: 27782102
Chem Rev. 2002 Apr;102(4):1091-134
pubmed: 11942788
Nat Rev Cardiol. 2018 May;15(5):292-316
pubmed: 29388567
Front Pharmacol. 2020 May 19;11:727
pubmed: 32508651
Br J Pharmacol. 2019 Jan;176(2):246-255
pubmed: 30288739
Cardiovasc Res. 2019 Jan 1;115(1):168-178
pubmed: 29931049
Circulation. 2017 Aug 1;136(5):476-489
pubmed: 28487391